JesÃºs GonzÃ¡lez-Bosquet

List of Publications by Year
in descending order

76 papers	3,963 citations

218677	118850
26 h-index	62 g-index

76 all docs	76 docs citations

76 times ranked	6688 citing authors

#	Article	IF	Citations
1	Multiple loci identified in a genome-wide association study of prostate cancer. Nature Genetics, 2008, 40, 310-315.	21.4	871
2	A multistage genome-wide association study in breast cancer identifies two new risk alleles at 1p11.2 and 14q24.1 (RAD51L1). Nature Genetics, 2009, 41, 579-584.	21.4	487
3	MUC16 (CA125): tumor biomarker to cancer therapy, a work in progress. Molecular Cancer, 2014, 13, 129.	19.2	372
4	Identification of a new prostate cancer susceptibility locus on chromosome 8q24. Nature Genetics, 2009, 41, 1055-1057.	21.4	218
5	Current Issues in the Management of Endometrial Cancer. Mayo Clinic Proceedings, 2008, 83, 97-112.	3.0	128
6	Long-term survival and disease recurrence in patients with primary squamous cell carcinoma of the vulva. Gynecologic Oncology, 2005, 97, 828-833.	1.4	114
7	The impact of multi-modal therapy on survival for uterine carcinosarcomas. Gynecologic Oncology, 2010, 116, 419-423.	1.4	114
8	Genome-wide association studies in cancer--current and future directions. Carcinogenesis, 2010, 31, 111-120.	2.8	100
9	Identification and molecular characterization of a new ovarian cancer susceptibility locus at 17q21.31. Nature Communications, 2013, 4, 1627.	12.8	98
10	BAD Phosphorylation Determines Ovarian Cancer Chemosensitivity and Patient Survival. Clinical Cancer Research, 2011, 17, 6356-6366.	7.0	97
11	Fine mapping and functional analysis of a common variant in *MSMB* on chromosome 10q11.2 associated with prostate cancer susceptibility. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 7933-7938.	7.1	96
12	*LIN28B* Polymorphisms Influence Susceptibility to Epithelial Ovarian Cancer. Cancer Research, 2011, 71, 3896-3903.	0.9	75
13	Squamous Cell Carcinoma of the Vulva Stage IA: Long-Term Results. Gynecologic Oncology, 2000, 76, 24-27.	1.4	71
14	Primary Squamous Cell Cancer of the Vulva: Radical versus Modified Radical Vulvar Surgery. Gynecologic Oncology, 1998, 71, 116-121.	1.4	68
15	Patterns of inguinal groin metastases in squamous cell carcinoma of the vulva. Gynecologic Oncology, 2007, 105, 742-746.	1.4	66
16	Epigenetic-mediated upregulation of progesterone receptor B gene in endometrial cancer cell lines. Gynecologic Oncology, 2005, 99, 135-141.	1.4	63
17	Analysis of gene expression in stage I serous tumors identifies critical pathways altered in ovarian cancer. Gynecologic Oncology, 2009, 114, 3-11.	1.4	57
18	Detection of Somatic Mutations by High-Resolution DNA Melting (HRM) Analysis in Multiple Cancers. PLoS ONE, 2011, 6, e14522.	2.5	52

#	Article	IF	Citations
19	Cytokeratin staining of resected lymph nodes may improve the sensitivity of surgical staging for endometrial cancerâ˜†. Gynecologic Oncology, 2003, 91, 518-525.	1.4	43
20	Fine mapping of a region of chromosome 11q13 reveals multiple independent loci associated with risk of prostate cancer. Human Molecular Genetics, 2011, 20, 2869-2878.	2.9	43
21	Common genetic variation in the sex hormone metabolic pathway and endometrial cancer risk: pathway-based evaluation of candidate genes. Carcinogenesis, 2010, 31, 827-833.	2.8	42
22	Risk of occult inguinofemoral lymph node metastasis from squamous carcinoma of the vulva. International Journal of Radiation Oncology Biology Physics, 2003, 57, 419-424.	0.8	41
23	Analysis of Chemotherapeutic Response in Ovarian Cancers Using Publicly Available High-Throughput Data. Cancer Research, 2014, 74, 3902-3912.	0.9	34
24	Prediction of chemo-response in serous ovarian cancer. Molecular Cancer, 2016, 15, 66.	19.2	33
25	Merkel Cell Carcinoma of the Vulva. Gynecologic Oncology, 1997, 64, 526-532.	1.4	30
26	Interval debulking surgery is not worth the wait: a National Cancer Database study comparing primary cytoreductive surgery versus neoadjuvant chemotherapy. International Journal of Gynecological Cancer, 2020, 30, 845-852.	2.5	29
27	A phase II trial of docetaxel and bevacizumab in recurrent ovarian cancer within 12 months of prior platinum-based chemotherapy. Gynecologic Oncology, 2013, 130, 19-24.	1.4	28
28	No Association between <i>FTO</i> or <i>HHEX</i> and Endometrial Cancer Risk. Cancer Epidemiology Biomarkers and Prevention, 2010, 19, 2106-2109.	2.5	24
29	Differential DNA methylation in high-grade serous ovarian cancer (HGSOC) is associated with tumor behavior. Scientific Reports, 2019, 9, 17996.	3.3	24
30	A novel c-Met inhibitor, MK8033, synergizes with carboplatin plus paclitaxel to inhibit ovarian cancer cell growth. Oncology Reports, 2013, 29, 2011-2018.	2.6	23
31	High stathmin expression is a marker for poor clinical outcome in endometrial cancer: An NRG oncology group/gynecologic oncology group study. Gynecologic Oncology, 2017, 146, 247-253.	1.4	23
32	BCL2 antagonist of cell death kinases, phosphatases, and ovarian cancer sensitivity to cisplatin. Journal of Gynecologic Oncology, 2012, 23, 35.	2.2	22
33	Comprehensive resequence analysis of a 97Âkb region of chromosome 10q11.2 containing the MSMB gene associated with prostate cancer. Human Genetics, 2009, 126, 743-750.	3.8	21
34	Dysregulation of miR-181c expression influences recurrence of endometrial endometrioid adenocarcinoma by modulating NOTCH2 expression: An NRG Oncology/Gynecologic Oncology Group study. Gynecologic Oncology, 2017, 147, 648-653.	1.4	21
35	The BCL2 antagonist of cell death pathway influences endometrial cancer cell sensitivity to cisplatin. Gynecologic Oncology, 2012, 124, 119-124.	1.4	20
36	MicroRNA Processing and Binding Site Polymorphisms Are Not Replicated in the Ovarian Cancer Association Consortium. Cancer Epidemiology Biomarkers and Prevention, 2011, 20, 1793-1797.	2.5	19

#	Article	IF	Citations
37	Comparison of gene expression patterns between avian and human ovarian cancers. Gynecologic Oncology, 2011, 120, 256-264.	1.4	18
38	Human cancer cell line microRNAs associated with in vitro sensitivity to paclitaxel. Oncology Reports, 2014, 31, 376-383.	2.6	18
39	Characterizing the Efficacy of Fermented Wheat Germ Extract Against Ovarian Cancer and Defining the Genomic Basis of Its Activity. International Journal of Gynecological Cancer, 2012, 22, 960-967.	2.5	17
40	<p>An integrated prediction model of recurrence in endometrial endometrioid cancers</p>. Cancer Management and Research, 2019, Volume 11, 5301-5315.	1.9	17
41	Differentially expressed genes in preimplantation human embryos: potential candidate genes for blastocyst formation and implantation. Journal of Assisted Reproduction and Genetics, 2016, 33, 1017-1025.	2.5	15
42	Factors associated with improved toxicity and tolerability of intraperitoneal chemotherapy in advanced-stage epithelial ovarian cancers. American Journal of Obstetrics and Gynecology, 2013, 208, 501.e1-501.e7.	1.3	14
43	Creation and validation of models to predict response to primary treatment in serous ovarian cancer. Scientific Reports, 2021, 11, 5957.	3.3	13
44	p53 mutation status is a primary determinant of placenta-specific protein 1 expression in serous ovarian cancers. International Journal of Oncology, 2017, 50, 1721-1728.	3.3	12
45	A Prediction Model for Preoperative Risk Assessment in Endometrial Cancer Utilizing Clinical and Molecular Variables. International Journal of Molecular Sciences, 2019, 20, 1205.	4.1	12
46	Molecular Characterization of Non-responders to Chemotherapy in Serous Ovarian Cancer. International Journal of Molecular Sciences, 2019, 20, 1175.	4.1	11
47	Gene expression data reveal common pathways that characterize the unifocal nature of ovarian cancer. American Journal of Obstetrics and Gynecology, 2013, 209, 576.e1-576.e16.	1.3	10
48	Placenta-Specific Protein 1 Expression in Human Papillomavirus 16/18â€"Positive Cervical Cancers Is Associated With Tumor Histology. International Journal of Gynecological Cancer, 2017, 27, 784-790.	2.5	9
49	Small bowel obstruction associated with post-hysterectomy vaginal vault prolapse. Obstetrics and Gynecology, 2003, 102, 524-526.	2.4	8
50	Hepatic resection for metachronous metastases from ovarian carcinoma. Hpb, 2006, 8, 93-96.	0.3	8
51	Molecular determinants for lymph node metastasis in clinically early-stage endometrial cancer. Oncology Letters, 2016, 11, 323-329.	1.8	8
52	The miR-503 cluster is coordinately under-expressed in endometrial endometrioid adenocarcinoma and targets many oncogenes, cell cycle genes, DNA repair genes and chemotherapy response genes. OncoTargets and Therapy, 2018, Volume 11, 7205-7211.	2.0	8
53	The O-glycan pathway is associated with in vitro sensitivity to gemcitabine and overall survival from ovarian cancer. International Journal of Oncology, 2012, 41, 179-88.	3.3	7
54	Gene Expression Signature-Based Prediction of Lymph Node Metastasis in Patients With Endometrioid Endometrial Cancer. International Journal of Gynecological Cancer, 2018, 28, 260-266.	2.5	7

#	Article	IF	Citations
55	Identification of Novel lncRNAs in Ovarian Cancer and Their Impact on Overall Survival. International Journal of Molecular Sciences, 2021, 22, 1079.	4.1	7
56	Bacterial, Archaea, and Viral Transcripts (BAVT) Expression in Gynecological Cancers and Correlation with Regulatory Regions of the Genome. Cancers, 2021, 13, 1109.	3.7	7
57	Disparity of ovarian cancer survival between urban and rural settings. International Journal of Gynecological Cancer, 2022, 32, 540-546.	2.5	7
58	Prediction of Optimal Cytoreductive Surgery of Serous Ovarian Cancer With Gene Expression Data. International Journal of Gynecological Cancer, 2015, 25, 1000-1009.	2.5	6
59	Stratification of endometrioid endometrial cancer patients into risk levels using somatic mutations. Gynecologic Oncology, 2016, 142, 150-157.	1.4	6
60	Population Substructure Has Implications in Validating Next-Generation Cancer Genomics Studies with TCGA. International Journal of Molecular Sciences, 2019, 20, 1192.	4.1	6
61	Prediction of Epithelial Ovarian Cancer Outcomes With Integration of Genomic Data. Clinical Obstetrics and Gynecology, 2020, 63, 92-108.	1.1	6
62	PP2A and E3 ubiquitin ligase deficiencies: Seminal biological drivers in endometrial cancer. Gynecologic Oncology, 2021, 162, 182-189.	1.4	6
63	Fine mapping of 14q24.1 breast cancer susceptibility locus. Human Genetics, 2012, 131, 479-490.	3.8	5
64	Gynecologic Oncology: Challenges of Minimally Invasive Surgery In a Field of Maximal Complexities. Clinical Obstetrics and Gynecology, 2020, 63, 30-39.	1.1	5
65	Association of a novel endometrial cancer biomarker panel with prognostic risk, platinum insensitivity, and targetable therapeutic options. PLoS ONE, 2021, 16, e0245664.	2.5	5
66	Identification of Novel Fusion Transcripts in High Grade Serous Ovarian Cancer. International Journal of Molecular Sciences, 2021, 22, 4791.	4.1	4
67	Role of metadherin in estrogen-regulated gene expression. International Journal of Molecular Medicine, 2017, 40, 303-310.	4.0	3
68	A nuclear polymorphism at the 8q24 region is associated with improved survival time and chemoâ€‘response in highâ€‘grade serous ovarian cancer. Oncology Letters, 2021, 22, 733.	1.8	3
69	The Synthetic Curcumin Analog HO-3867 Rescues Suppression of PLAC1 Expression in Ovarian Cancer Cells. Pharmaceuticals, 2021, 14, 942.	3.8	3
70	Identifying novel ovarian tumor biomarkers through mining of the transcriptome of circulating immune cells: A proofâ€‘ofâ€‘concept study. American Journal of Reproductive Immunology, 2021, 86, e13469.	1.2	2
71	Association analysis of a chemo-response signature identified within The Cancer Genome Atlas aimed at predicting genetic risk for chemo-response in ovarian cancer. International Journal of Molecular Epidemiology and Genetics, 2016, 7, 41-4.	0.4	2
72	The Impact of Multimodal Therapy on Survival for Uterine Carcinosarcomas. Obstetrical and Gynecological Survey, 2010, 65, 313-314.	0.4	1

#	Article	IF	Citations
73	Foreword: New and Novel Treatments for Gynecologic Cancer. Clinical Obstetrics and Gynecology, 2020, 63, 1-2.	1.1	0
74	Principles of analysis of germline genetics. , 2009, , 13-35.		0
75	Development of an Intracellular, DNA Methyltransferase-Specific, and Gene-Specific Assay for Studying Dynamic DNA Methylation. Current Pharmaceutical Design, 2014, 20, 1664-1673.	1.9	0
76	Clinicopathological predictors of chemoresponsiveness in epithelial ovarian cancer: a preliminary institutional study. Proceedings in Obstetrics and Gynecology, 2015, 5, 1-13.	0.1	0